MHRAsafety guidance72% confidence
Clinical trials for medicines: collection, verification and reporting of safety events
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Gilead.
Regulatory Analysis
Guidance on the collection, verification, and reporting of safety events in clinical trials of an investigational medicinal product.
Supporting Context
- Therapeutic area
- Infectious Disease · HIV
- Sub-indication
- General
Related signal: Islatravir and Lenacapavir Show Sustained Virologic Suppression in Phase 3 HIV Trials